ALTANA Pharma AG Receives Approval To Market Ciclesonide Nasal Spray In The U.S.

October 23, 2006 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

BAD HOMBURG & KONSTANZ, Germany--(BUSINESS WIRE)--ALTANA AG (NYSE:AAA)(FWB:ALT)(GER:ALT) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for OMNARIS™ (Ciclesonide nasal spray), 200µ once-daily.

>>> Discuss This Story

Twitter
LinkedIn
Facebook
Email
Print

FDA Approvals Europe